CELLDEX THERAPEUTICS INC NEW's ticker is CLDX and the CUSIP is 15117B202. A total of 116 filers reported holding CELLDEX THERAPEUTICS INC NEW in Q1 2021. The put-call ratio across all filers is 0.66 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2022 | $2,108,000 | -91.0% | 75,000 | -91.3% | 0.32% | -92.9% |
| Q2 2022 | $23,324,000 | -20.8% | 865,116 | 0.0% | 4.59% | -3.8% |
| Q1 2022 | $29,466,000 | -11.9% | 865,116 | 0.0% | 4.77% | +4.5% |
| Q4 2021 | $33,428,000 | -43.6% | 865,116 | -21.2% | 4.57% | -40.0% |
| Q3 2021 | $59,290,000 | +42.9% | 1,098,174 | -11.5% | 7.62% | +51.3% |
| Q2 2021 | $41,486,000 | +62.3% | 1,240,610 | 0.0% | 5.03% | +81.5% |
| Q1 2021 | $25,557,000 | +82.3% | 1,240,610 | +55.1% | 2.77% | +34.5% |
| Q4 2020 | $14,016,000 | +18.1% | 800,000 | 0.0% | 2.06% | -11.2% |
| Q3 2020 | $11,864,000 | – | 800,000 | – | 2.32% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Kynam Capital Management, LP | 1,605,390 | $71,552,232 | 10.98% |
| Octagon Capital Advisors LP | 761,398 | $33,935,509 | 5.28% |
| TSP Capital Management Group, LLC | 269,895 | $12,029,225 | 4.50% |
| Redmile Group, LLC | 1,977,451 | $88,134,991 | 3.60% |
| COMMODORE CAPITAL LP | 495,823 | $22,099 | 3.33% |
| Tri Locum Partners LP | 176,109 | $7,849,000 | 3.18% |
| ACUTA CAPITAL PARTNERS, LLC | 115,000 | $5,125,550 | 3.15% |
| Ikarian Capital, LLC | 267,476 | $11,921,406 | 2.88% |
| RTW INVESTMENTS, LP | 3,084,215 | $137,463,463 | 2.81% |
| Eversept Partners, LP | 558,774 | $24,904,557 | 2.18% |